Jerasutus S, et al. - An open‐label clinical trial was conducted to assess the therapeutic effectiveness, safety, and tolerability of topical 1% encapsulated terbinafine hydrochloride gel for the treatment of pediatric tinea capitis. This investigation was carried out on 10 children with a clinical and mycologically confirmed diagnosis of tinea capitis. The topical 1% encapsulated terbinafine hydrochloride gel was prescribed to each child to be applied twice daily to the full scalp for 4 weeks. Two weeks after completion of treatment, clinical and mycological examinations were assessed. During the treatment and follow‐up periods, monitoring was performed for associated side effects. The sample consisted of ten male patients with a mean age of 10.3 years. This preliminary study showed that topical 1% encapsulated terbinafine hydrochloride gel was an efficient treatment in children with tinea capitis. No significant side effects have been reported